Therapeutic targeting of preleukemia cells in a mouse model of NPM1 mutant acute myeloid leukemia
The initiating mutations that contribute to cancer development are sometimes present in premalignant cells. Whether therapies targeting these mutations can eradicate premalignant cells is unclear. Acute myeloid leukemia (AML) is an attractive system for investigating the effect of preventative treatment because this disease is often preceded by a premalignant state (clonal hematopoiesis or myelodysplastic syndrome). In Npm1c/Dnmt3a mutant knock-in mice, a model of AML development, leukemia is preceded by a period of extended myeloid progenitor cell proliferation and self-renewal. We found that this self-renewal can be reve...
Source: ScienceNOW - January 30, 2020 Category: Science Authors: Uckelmann, H. J., Kim, S. M., Wong, E. M., Hatton, C., Giovinazzo, H., Gadrey, J. Y., Krivtsov, A. V., Rücker, F. G., Döhner, K., McGeehan, G. M., Levine, R. L., Bullinger, L., Vassiliou, G. S., Armstrong, S. A. Tags: Medicine, Diseases reports Source Type: news

Reducing Blood Cancer Patients' Need for Transfusions
January 21, 2020—(BRONX, NY)—A clinical trial has found the drug luspatercept significantly reduced the need for blood transfusions in people with lower-risk myelodysplastic syndromes (MDS), a group of bone marrow disorders that leave people with many defective blood cells and too few normal ones. Approval by the Food and Drug Administration (FDA) would make luspatercept the first new drug available to MDS patients in 12 years.Results of the phase 3 clinical trial were published online January 9 in the New England Journal of Medicine (NEJM). (Source: Einstein News)
Source: Einstein News - January 22, 2020 Category: Universities & Medical Training Source Type: news

Drug Reduces Need for Transfusions in Some Patients With Myelodysplastic Syndromes Drug Reduces Need for Transfusions in Some Patients With Myelodysplastic Syndromes
Therapy every 3 weeks with the drug luspatercept dramatically reduced the need for blood transfusions in a subset of patients with lower-risk myelodysplastic syndromes (MDS), according to results from the MEDALIST study reported in the Jan. 9 New England Journal of Medicine.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - January 10, 2020 Category: Consumer Health News Tags: Medscape Today News Source Type: news

Luspatercept Mitigates Anemia in Lower - Risk Myelodysplastic Syndromes
Transfusion burden reduced in patients with lower - risk myelodysplastic syndromes with ring sideroblasts (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - January 9, 2020 Category: Cancer & Oncology Tags: Oncology, Pharmacy, Journal, Source Type: news

Luspatercept Mitigates Anemia in Lower-Risk Myelodysplastic Syndromes
WEDNESDAY, Jan. 8, 2020 -- For patients with lower-risk myelodysplastic syndromes with ring sideroblasts who have been receiving regular red-cell transfusions, luspatercept reduces the severity of anemia compared with placebo, according to a study... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - January 8, 2020 Category: Pharmaceuticals Source Type: news

Medicare Coverage of HCT Recommended for Older Adults With Myelodysplastic Syndrome Medicare Coverage of HCT Recommended for Older Adults With Myelodysplastic Syndrome
A study of hematopoietic stem cell transplantation (HCT) for adults with myelodysplastic syndrome (MDS) showed that patients 65 and older had comparable outcomes to those ages 55 to 64, leading the authors to recommend that the US Centers for Medicare and Medicaid Services cover HCT.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - December 24, 2019 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Research revises classification of acute myeloid leukemia & myelodysplastic syndrome
(St. Jude Children's Research Hospital) Findings presented as a late-breaking abstract at the American Society of Hematology annual meeting by St. Jude Children's Research Hospital showcase the power and potential of combining genomic and transcriptomic data. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - December 10, 2019 Category: Cancer & Oncology Source Type: news

Isavuconazole (ISAV) as Primary Anti-Fungal Prophylaxis (PAP) in Patients (pts) with Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS): An Open-Label, Prospective Study
Conference abstracts (Source: The Aspergillus Website - updates)
Source: The Aspergillus Website - updates - November 12, 2019 Category: Respiratory Medicine Authors: MeganB Source Type: news

Isavuconazole (ISAV) As Primary Anti-Fungal Prophylaxis in Acute Myeloid Leukemia or Myelodysplastic Syndrome: An Open-Label, Prospective Study
Conference abstracts (Source: The Aspergillus Website - updates)
Source: The Aspergillus Website - updates - October 8, 2019 Category: Respiratory Medicine Authors: MeganB Source Type: news

Causative Organisms and Resistance Patterns of Infection in Patients with Myelodysplastic Syndrome (MDS): A 20 Year Retrospective Analysis
Conference abstracts (Source: The Aspergillus Website - updates)
Source: The Aspergillus Website - updates - October 7, 2019 Category: Respiratory Medicine Authors: MeganB Source Type: news

Epidemiology of Visceral Mycoses in Patients with Acute Leukemia and Myelodysplastic Syndrome: Analyzing the National Autopsy Database in Japan
Conference abstracts (Source: The Aspergillus Website - updates)
Source: The Aspergillus Website - updates - October 7, 2019 Category: Respiratory Medicine Authors: MeganB Source Type: news

Pulmonary Infections in Patients with Myelodysplastic Syndromes Receiving Azacytidine Treatment
Conference abstracts (Source: The Aspergillus Website - updates)
Source: The Aspergillus Website - updates - October 5, 2019 Category: Respiratory Medicine Authors: MeganB Source Type: news

$5M grant to help Wash U research blood disorder therapies
The Washington University School of Medicine has received a $5 million grant from the Edward P. Evans Foundation to create a new center that will research rare blood disorders. The center will focus on a specific set of disorders, called myelodysplastic syndromes (MDS), which prohibits the body from creating enough healthy blood cells, according to a release. Dr. Matthew Walter will lead the center. Officials said MDS is hard to detect, with patients suffering from fat igue and shortness of breath.… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - September 12, 2019 Category: Biotechnology Authors: Vince Brennan Source Type: news

Couple Settles With Last Defendant In Benzene Suit On Eve Of Trial
OAKLAND, Calif. - A law firm representing a couple claiming that the man's exposure to benzene-containing products while working as an automobile mechanic caused him to develop myelodysplastic syndrome (MDS) announced July 1 that they had reached a settlement in California state court with the last defendant in the action on the eve of trial, bringing the total settlement amount to $6.3 million (Jimmy H. Thomas, et al. v. AZKO Nobel Coatings Inc., et al., No. RG-17-882514, Calif. Super., Alameda Co.). (Source: LexisNexis® Mealey's™ Emerging Toxic Torts Legal News)
Source: LexisNexis® Mealey's™ Emerging Toxic Torts Legal News - July 10, 2019 Category: Medical Law Source Type: news

Study to Evaluate the Safety and Efficacy of the Combination Therapy of Ibrexafungerp (SCY-078) With Voriconazole in Patients With Invasive Pulmonary Aspergillosis (SCYNERGIA)
This is a multicenter, randomized, double-blind, two-arm study to evaluate the safety, tolerability, efficacy and PK of the combination therapy of SCY-078 plus voriconazole compared to those of voriconazole monotherapy in male and female subjects 18 years of age and older with a hematological malignancy (HM) or a myelodysplastic syndrome or aplastic anemia or hematopoietic cell transplantation (HCT) and a probable or proven invasive pulmonary aspergillosis based on EORTCMSG criteria. In addition, all subjects must be positive ( ≥0.5) for serum GMI. (Source: The Aspergillus Website - updates)
Source: The Aspergillus Website - updates - July 3, 2019 Category: Respiratory Medicine Authors: GAtherton Source Type: news

Boy, 11, who has a rare blood cancer has been told there is nothing more doctors can do
Oliver Brown, from Devon, was told by doctors he had myelodysplastic syndrome when he was eight years old. At the time, doctors said he was the only boy in the country with the disease. (Source: the Mail online | Health)
Source: the Mail online | Health - June 25, 2019 Category: Consumer Health News Source Type: news

Transfusion Dose Density Affects Myelodysplastic Syndrome Survival
Negative effect of transfusion treatment on PFS occurs at density less than 3 units/16 weeks (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - June 24, 2019 Category: Cancer & Oncology Tags: Oncology, Journal, Source Type: news

Transfusion Dose Density Affects Myelodysplastic Syndrome Survival
MONDAY, June 24, 2019 -- Transfusion dose density is an independent prognostic factor for progression-free survival (PFS) in patients with myelodysplastic syndromes treated with red blood cell transfusions (RBCTs), according to a study published... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - June 24, 2019 Category: Pharmaceuticals Source Type: news

Celgene Corporation and Acceleron Pharma Announce U.S. FDA Accepts Luspatercept Biologics License Application in Myelodysplastic Syndromes and Beta-Thalassemia
SUMMIT, N.J.& CAMBRIDGE, Mass.June 04, 2019 --(BUSINESS WIRE)-- Celgene Corporation (NASDAQ: CELG) and Acceleron Pharma Inc. (NASDAQ: XLRN) today announced that the U.S. Food and Drug Administration (FDA) has accepted Celgene’s Biologics... (Source: Drugs.com - New Drug Applications)
Source: Drugs.com - New Drug Applications - June 4, 2019 Category: Drugs & Pharmacology Source Type: news

Lenalidomid Approved by FDA for Follicular and Marginal Zone Lymphoma
This thalidomide analogue is also indicated for multiple myeloma and myelodysplastic syndromes. (Source: CancerNetwork)
Source: CancerNetwork - May 28, 2019 Category: Cancer & Oncology Authors: Drew Boxler Source Type: news

Lenalidomide Approved by FDA for Follicular and Marginal Zone Lymphoma
This thalidomide analogue is also indicated for multiple myeloma and myelodysplastic syndromes. (Source: CancerNetwork)
Source: CancerNetwork - May 28, 2019 Category: Cancer & Oncology Authors: Drew Boxler Source Type: news

Newtown biopharm firm could reap $50M from Chinese licensing deal
Onconova Therapeutics Inc. could receive more than $50 million under a licensing deal it signed Monday for its lead experimental cancer therapy. HanX Biopharmaceuticals acquired the rights in Greater China to rigosertib, a new drug candidate Bucks County-based Onconova is developing initially as a treatment for patients at higher risks for developing myelodysplastic syndromes of MDA. MDS is a type of cancer that can occur when the blood-fo rming cells in bone marrow become abnormal. Under the… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - May 13, 2019 Category: Biotechnology Authors: John George Source Type: news

Aprea Therapeutics Receives FDA Fast Track Designation and Orphan Drug Designation for APR-246 for the Treatment of Myelodysplastic Syndromes (MDS)
BOSTON and STOCKHOLM, April 16, 2019 -- (Healthcare Sales & Marketing Network) -- Aprea Therapeutics, a privately held, clinical stage biopharmaceutical company developing novel anticancer therapies targeting the tumor suppressor protein p53, today announ... Biopharmaceuticals, Oncology, FDA Aprea Therapeutics, p53, myelodysplastic syndromes (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - April 16, 2019 Category: Pharmaceuticals Source Type: news

Aprea Therapeutics Adds New Investor to Series C Financing
Janus Henderson Investors joins Investor Group BOSTON and STOCKHOLM, Feb. 27, 2019 -- (Healthcare Sales & Marketing Network) -- Aprea Therapeutics, a clinical-stage biotechnology company developing novel anticancer therapies targeting the p53 tumor sup... Biopharmaceuticals, Oncology, Venture Capital Aprea Therapeutics, p53, myelodysplastic syndromes (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - February 27, 2019 Category: Pharmaceuticals Source Type: news

Does Chemotherapy Increase the Risks of Myelodysplastic Syndrome and Acute Myeloid Leukemia?
The study, published in JAMA Oncology, examined whether treatment of 22 solid tumor types was associated with two therapy-related conditions. (Source: CancerNetwork)
Source: CancerNetwork - February 7, 2019 Category: Cancer & Oncology Authors: Christina Bennett, MS Source Type: news

Myelodysplastic Syndrome/AML Risk Increased After Chemo
Since 2000, risks for therapy - related myelodysplastic syndrome, AML up after chemo for solid cancers (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - January 4, 2019 Category: Cancer & Oncology Tags: Oncology, Pharmacy, Journal, Source Type: news

Myelodysplastic Syndrome/AML Risk Increased After Chemo
FRIDAY, Jan. 4, 2019 -- The risks for therapy-related myelodysplastic syndrome or acute myeloid leukemia (tMDS/AML) are elevated after chemotherapy use for solid tumors, according to a study published online Dec. 20 in JAMA Oncology. Lindsay M.... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - January 4, 2019 Category: Pharmaceuticals Source Type: news

Study finds elevated risk of rare blood cancers after chemotherapy for most solid tumors
(NIH/National Cancer Institute) Findings from a new study by researchers at the National Cancer Institute (NCI) show that patients treated with chemotherapy for most solid tumors during 2000-2014 experienced an increased risk of therapy-related myelodysplastic syndrome/acute myeloid leukemia (tMDS/AML). The study was published December 20, 2018, in JAMA Oncology. NCI is part of the National Institutes of Health. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - December 20, 2018 Category: Cancer & Oncology Source Type: news

Identifying Molecular Markers of Relapse in Myelodysplastic Syndrome
In this month's installment ofAsk the PI,ONCOLOGY spoke with two authors of the study, Meagan A. Jacoby, MD, PhD, and Matthew Walter, MD, about their findings and what they might mean for practicing oncologists. (Source: CancerNetwork)
Source: CancerNetwork - December 17, 2018 Category: Cancer & Oncology Authors: Meagan A. Jacoby, MD, PhD, Matthew Walter, MD Source Type: news

Can Azacitidine Delay Relapse in MRD-Positive AML?
Azacitidine may delay or prevent relapse among patients with MRD-positive acute myeloid leukemia or myelodysplastic syndrome. (Source: CancerNetwork)
Source: CancerNetwork - December 13, 2018 Category: Cancer & Oncology Authors: Bryant Furlow Source Type: news

Model Improves Predictions of Myelodysplastic Syndrome Prognosis Model Improves Predictions of Myelodysplastic Syndrome Prognosis
For patients with myelodyplastic syndrome, a machine-learning model provides a look into the future and can predict outcomes for each individual.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - December 3, 2018 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Luspatercept Reduces Blood Transfusions in MDS and Beta-Thalassemia Luspatercept Reduces Blood Transfusions in MDS and Beta-Thalassemia
A novel agent reduced the need for blood transfusions in two separate patient populations: myelodysplastic syndromes (MDS) and beta-thalassemia.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - December 2, 2018 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Cleveland Clinic's Aziz Nazha, M.D., develops personalized prediction model for patients with MDS
(Cleveland Clinic) At the American Society of Hematology (ASH) Annual Meeting, Cleveland Clinic medical hematologist and oncologist Aziz Nazha, M.D., will present results of a personalized prediction model that surpassed current prediction models for Myelodysplastic Syndromes (MDS). (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - December 2, 2018 Category: Cancer & Oncology Source Type: news

Lixte Biotechnology Files an IND with the FDA to Conduct a Phase 1b/2 Trial of LB-100 in Patients with Myelodysplastic Syndrome at Moffitt Cancer Center
EAST SETAUKET, NY , Oct. 09, 2018 -- (Healthcare Sales & Marketing Network) -- Lixte Biotechnology Holdings, Inc. (OTCQB: LIXT) announced that it has submitted an IND to the FDA to conduct a Phase 1b/2 trial of the safety and therapeutic benefit of Lixte’s... Biopharmaceuticals, Oncology, FDA Lixte Biotechnology, protein phosphatases, Myelodysplastic Syndrome (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - October 9, 2018 Category: Pharmaceuticals Source Type: news

MD Anderson and Cyclacel Pharmaceuticals announce strategic alliance to study novel Cyclacel medicin
(University of Texas M. D. Anderson Cancer Center) The University of Texas MD Anderson Cancer Center and Cyclacel Pharmaceuticals, Inc., today announced a three-year strategic alliance agreement that will enable clinical evaluation for safety and efficacy of three Cyclacel medicines in patients with hematological malignancies, including chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), myelodysplastic syndrome (MDS) and other advanced leukemias. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - October 4, 2018 Category: Cancer & Oncology Source Type: news

Mayo researchers develop new genetics-based prognostic tool for myelodysplastic syndrome
ROCHESTER, Minn. ? Researchers at Mayo Clinic have developed a new genetics-based prognostic tool for myelodysplastic syndrome. Their findings are published in the October print issue of Mayo Clinic Proceedings. ?Myelodysplastic syndrome is one of the most frequent blood cancers affecting the elderly with annual incidence exceeding 50 cases per 100,000 in people 65 years [...] (Source: Mayo Clinic Research News)
Source: Mayo Clinic Research News - October 1, 2018 Category: Research Source Type: news

Genetic testing helps predict disease recurrence in myelodysplastic syndrome
(Washington University School of Medicine) A DNA-based analysis of blood cells soon after a stem cell transplant can predict likelihood of disease recurrence in patients with myelodysplastic syndrome (MDS), a group of cancerous disorders characterized by dysfunctional blood cells, according to new research at Washington University School of Medicine in St. Louis. Such a practice could help doctors identify patients at high risk of disease recurrence early after a transplant and help guide treatment decisions. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - September 12, 2018 Category: Cancer & Oncology Source Type: news

Scientists close in on mystery surrounding dangerous blood syndromes
(Cincinnati Children's Hospital Medical Center) Scientists may be on the road to solving the mystery of a group of mostly incurable blood diseases called myelodysplastic syndromes (MDS), which cause people to have immature, malfunctioning bone marrow cells that fuel a diverse set of health problems and can lead to leukemia. Researchers report in the journal Cancer Discovery identifying a gene that in laboratory experiments fuels the biological processes that cause the different types of MDS that physicians see in patients. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - August 23, 2018 Category: Cancer & Oncology Source Type: news

Renal Cell Carcinoma and Myelodysplastic Syndrome Show Epigenetic Association
Hypermethylation has been documented in some myeloid disorders including myelodysplastic syndrome (MDS) and in renal cell carcinoma (RCC). A group at the Mayo Clinic noticed the epigenetic marking patterns between these vastly different conditions and wondered if there was a connection. The group found that there was a strong association.08/09/2018 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - August 9, 2018 Category: Urology & Nephrology Source Type: news

MD Anderson and Jazz Pharmaceuticals collaborate to evaluate treatment options for hematol
(University of Texas M. D. Anderson Cancer Center) The University of Texas MD Anderson Cancer Center and Jazz Pharmaceuticals plc today announced a five-year collaboration agreement with a goal of evaluating therapies for multiple hematologic malignancies, including acute myeloid leukemia (AML) and myelodysplastic syndromes. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - August 6, 2018 Category: Cancer & Oncology Source Type: news

Amgen And MD Anderson Announce Collaboration To Accelerate Early Stage Treatments For Leukemia, Myelodysplastic Syndromes, Multiple Myeloma, Small-Cell Lung And Other Small-Cell Cancers
Efforts to Focus on Pre-Clinical and Clinical Research for up to 16 Early-Stage Programs Across Various Types of Cancer Multi-Year Agreements Build on Long-Term Partnership in Immuno-Oncology, Including BiTE® Therapies and now CAR T Programs THOUSAND OAKS, Calif. and HOUSTON, May 31, 2018 /PRNewswire/ -- Amgen (NASDAQ:AMGN) and The University of Texas MD Anderson Cancer Center today announced two multi-year collaboration agreements aimed at accelerating development of a variety of Amgen's early-stage oncology therapies for patients with leukemia, myelodysplastic syndromes, multiple myeloma, small-cell lung ...
Source: Amgen News Release - May 31, 2018 Category: Pharmaceuticals Tags: Uncategorized Source Type: news

MD Anderson and Amgen to accelerate early-stage treatments for several cancer types
(University of Texas M. D. Anderson Cancer Center) The University of Texas MD Anderson Cancer Center and Amgen today announced two multi-year collaboration agreements aimed at accelerating development of a variety of Amgen's early-stage oncology therapies for patients with leukemia, myelodysplastic syndromes, multiple myeloma, small-cell lung cancer, and other non-lung cancers with small-cell histologies. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - May 31, 2018 Category: Cancer & Oncology Source Type: news

Mayo study identifies new potential treatment option for triple negative breast cancer
(Mayo Clinic) In a recent study published in the Journal of Clinical Investigation, Mayo Clinic researchers identified that an FDA drug approved for myelodysplastic syndrome may be useful to treat triple-negative breast cancer, which is one of the most aggressive and lethal types of breast cancer. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - May 21, 2018 Category: Cancer & Oncology Source Type: news

Mayo study identifies new potential treatment option for triple negative breast cancer
In this study, Mayo investigators identified that the [...] (Source: Mayo Clinic Research News)
Source: Mayo Clinic Research News - May 16, 2018 Category: Research Source Type: news

Implications of Mutation Profiling in Myeloid Malignancies —PART 1: Myelodysplastic Syndromes and Acute Myeloid Leukemia
In this first part of our two-part review, we introduce mutation profiling as a relevant clinical tool for hematologists treating patients with myeloid malignancies. (Source: CancerNetwork)
Source: CancerNetwork - April 16, 2018 Category: Cancer & Oncology Authors: Douglas Tremblay, MD John O. Mascarenhas, MD Kelsey Sokol, MD Raajit Rampal, MD Sheena Bhalla, MD Tags: Acute Myeloid Leukemia Hematologic Malignancies Myelodysplastic Syndromes Oncology Journal Review Article Source Type: news

Novel Drug Shows Promise Against Acute Myeloid Leukemia
April 11, 2018—(BRONX, NY)—In a study published online today in Science Translational Medicine,Albert Einstein College of Medicine researchers report that an experimental peptide (small protein) drug shows promise against the often-lethal cancer acute myeloid leukemia (AML) and describe how the drug works at the molecular level. The findings have led to a Phase I/II clinical trial for patients with advanced AML and advanced myelodysplastic syndrome (MDS), now underway atMontefiore Health System. (Source: Einstein News)
Source: Einstein News - April 11, 2018 Category: Universities & Medical Training Source Type: news

Novel drug shows promise against acute myeloid leukemia
(Albert Einstein College of Medicine) In a study published online today in Science Translational Medicine, Albert Einstein College of Medicine researchers report that an experimental peptide (small protein) drug shows promise against the often-lethal cancer acute myeloid leukemia (AML) and describe how the drug works at the molecular level. The findings have led to a Phase I/II clinical trial for patients with advanced AML and advanced myelodysplastic syndrome (MDS), now underway at Montefiore Health System. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - April 11, 2018 Category: Cancer & Oncology Source Type: news

Rigosertib May Benefit Some Patients with Myelodysplastic Syndromes
Although there are currently no approved second-line therapies for high-risk MDS, researchers have discovered that rigosertib has the potential to benefit this population of patients. (Source: CancerNetwork)
Source: CancerNetwork - February 27, 2018 Category: Cancer & Oncology Authors: John Schieszer Tags: Myelodysplastic Syndromes News Source Type: news

Trethera Corporation Announces FDA Clearance of Investigational New Drug Application for TRE-515
LOS ANGELES, Feb. 5, 2018 -- (Healthcare Sales & Marketing Network) -- Trethera Corporation, a biopharmaceutical company committed to developing novel drugs targeting cellular nucleotide metabolism for the treatment of cancer, today announced that the U.S... Biopharmaceuticals, Oncology, FDA Trethera, TRE-515, deoxycytidine kinase, myelodysplastic syndrome (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - February 5, 2018 Category: Pharmaceuticals Source Type: news